Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New malaria treatment plan put to the test in peru

NCT ID NCT05361486

Knowledge-focused Sponsor: Medicines for Malaria Venture Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a new way to treat Malaria Vivax is practical for healthcare workers in Peru. The plan includes a simple test to check a patient's G6PD enzyme level before giving one of two medicines, tafenoquine or primaquine. Researchers trained healthcare providers and followed up with patients after 3 days to see if the new steps were followed correctly. 187 patients took part, and the goal was to see if this approach could work in real-world clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

187 people

The number who actually took part.

Started

Aug 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* All Health Care Providers (HCPs) working in the selected facilities who are involved in the management of vivax patients * All patients aged 6 months onward, who have a confirmed P. vivax infection and who are treated in a Health Facility participating in the study.

Ages

6 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Health Care Providers: • All HCPs working in the selected facilities who are involved in the management of vivax patients. Inclusion criteria patients: * All patients aged 6 months onward, who have a confirmed P. vivax infection and who are treated in a study Health Facilities * Pregnant and lactating women, who have a contra-indication to both Primaquine and Tafenoquine, but for whom correct case management will be evaluated as part of the primary endpoints. * Patients providing informed consent and/or informed assent Exclusion criteria patients: • Patients with signs of severe infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria vivax are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malaria vivax

Contacts and locations

Locations

  • Nauta Nucleo- Base

    Nauta, Loreto, 16310, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.